Sage Therapeutics (SAGE)
(Delayed Data from NSDQ)
$6.96 USD
-0.26 (-3.60%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $6.96 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Balance Sheet
Fiscal Year End for Sage Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 755 | 1,272 | 1,742 | 2,100 | 1,008 |
Receivables | 83 | 14 | 19 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 32 | 51 | 40 | 23 | 27 |
Total Current Assets | 869 | 1,337 | 1,801 | 2,122 | 1,035 |
Net Property & Equipment | 2 | 3 | 3 | 7 | 9 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 7 | 6 | 6 | 5 | 6 |
Total Assets | 882 | 1,356 | 1,825 | 2,159 | 1,084 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 10 | 19 | 10 | 4 | 15 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 67 | 73 | 67 | 55 | 87 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 83 | 99 | 85 | 67 | 112 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 83 | 104 | 96 | 87 | 140 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 3,370 | 3,291 | 3,227 | 3,110 | 2,587 |
Retained Earnings | -2,570 | -2,028 | -1,495 | -1,037 | -1,644 |
Other Equity | -1 | -10 | -3 | 0 | 1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 800 | 1,253 | 1,729 | 2,072 | 945 |
Total Liabilities & Shareholder's Equity | 882 | 1,356 | 1,825 | 2,159 | 1,084 |
Total Common Equity | 800 | 1,253 | 1,729 | 2,072 | 945 |
Shares Outstanding | 60.00 | 59.40 | 58.90 | 52.00 | 51.80 |
Book Value Per Share | 13.33 | 21.09 | 29.36 | 39.85 | 18.24 |
Fiscal Year End for Sage Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 648 | 718 | 755 | 876 | 1,003 |
Receivables | 10 | 11 | 83 | 23 | 15 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 29 | 27 | 32 | 35 | 46 |
Total Current Assets | 687 | 755 | 869 | 933 | 1,064 |
Net Property & Equipment | 1 | 2 | 2 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 8 | 8 | 7 | 8 | 8 |
Total Assets | 697 | 768 | 882 | 950 | 1,082 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 6 | 10 | 11 | 9 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 59 | 52 | 67 | 115 | 80 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 69 | 62 | 83 | 133 | 97 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 69 | 62 | 83 | 133 | 98 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 3,410 | 3,385 | 3,370 | 3,358 | 3,326 |
Retained Earnings | -2,781 | -2,678 | -2,570 | -2,537 | -2,335 |
Other Equity | -1 | -1 | -1 | -4 | -6 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 628 | 706 | 800 | 817 | 984 |
Total Liabilities & Shareholder's Equity | 697 | 768 | 882 | 950 | 1,082 |
Total Common Equity | 628 | 706 | 800 | 817 | 984 |
Shares Outstanding | 61.00 | 60.10 | 60.00 | 59.90 | 59.70 |
Book Value Per Share | 10.30 | 11.74 | 13.33 | 13.63 | 16.49 |